Back
Results - Announcements
Marksans Pharma Ltd consolidated sales down 1.79% on year in Q2FY2026, net profit inched up 6.97%
12-Aug-2026, 03:05
Marksans Pharma Ltd share price gained 2.74% to Rs 278.9 after the company's net profit saw a marginal increase of 6.97% to Rs 159.41 crore, while revenue from operations eased by 1.79% to Rs 840.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, easing 4.41%. It has marginally improved by 1.16% over last one week and moving up by 11.70% in last one month while the market capitalization of Marksans Pharma Ltd has improved by 3.11% and 38% in the same period respectively. Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 206.57 crore in Q2 FY26, rallying 169.67% year-on-year, and gaining 3.28% quarter-on-quarter. EBITDA came in at Rs 188 crore, surging by 98.59% YoY and expanding by 17.09% sequentially. Total expenses softened by 4.72% to Rs 652.63 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 220.67 crore, contracting by 16.72% YoY, while employee benefits expense was at Rs 114.29 crore, rising by 7.05% YoY. For the TTM ended FY26, revenue from operations improved 12.51% to Rs 2950.94 crore, while net profit saw a mild growth of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48060% to Rs 518.25 crore, and PBT registered a growth of 11.23% to Rs 560.56 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25. Marksans Pharma Ltd rallied 32.97% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.04% during the same period.
Marksans Pharma Ltd share price gained 2.74% to Rs 278.9 after the company's net profit saw a marginal increase of 6.97% to Rs 159.41 crore, while revenue from operations eased by 1.79% to Rs 840.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, easing 4.41%. It has marginally improved by 1.16% over last one week and moving up by 11.70% in last one month while the market capitalization of Marksans Pharma Ltd has improved by 3.11% and 38% in the same period respectively. Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 206.57 crore in Q2 FY26, rallying 169.67% year-on-year, and gaining 3.28% quarter-on-quarter. EBITDA came in at Rs 188 crore, surging by 98.59% YoY and expanding by 17.09% sequentially. Total expenses softened by 4.72% to Rs 652.63 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 220.67 crore, contracting by 16.72% YoY, while employee benefits expense was at Rs 114.29 crore, rising by 7.05% YoY. For the TTM ended FY26, revenue from operations improved 12.51% to Rs 2950.94 crore, while net profit saw a mild growth of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48060% to Rs 518.25 crore, and PBT registered a growth of 11.23% to Rs 560.56 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25. Marksans Pharma Ltd rallied 32.97% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.04% during the same period.